by Mrudula Kulkarni
3 minutes
Entrada Therapeutics Promotes Dr. Sethuraman to President of Research and Development
Entrada promotes Dr. Sethuraman to lead R&D, advancing breakthrough intracellular therapeutics.
Entrada Therapeutics, a clinical-stage biopharmaceutical company focused on pioneering intracellular therapeutics, has promoted Natarajan Sethuraman, PhD, to the position of President of Research and Development. Dr. Sethuraman, who joined Entrada in 2017 as Chief Scientific Officer, has been a key figure in advancing the company’s innovative pipeline of Endosomal Escape Vehicle (EEV™)-therapeutics. His leadership has been instrumental in bringing the company’s ENTR-601-44 program into clinical trials and fostering a collaborative, innovative R&D environment.
Dipal Doshi, CEO of Entrada Therapeutics, praised Dr. Sethuraman’s contributions, stating that his broad expertise in end-to-end therapeutic development has helped shape the company’s efforts to bring life-changing treatments to patients. Doshi highlighted that Dr. Sethuraman's leadership has built a pipeline of proprietary intracellular therapeutics and a highly skilled team driven by passion and commitment.
Dr. Sethuraman expressed excitement about his new role, emphasizing the potential of Entrada’s technology to target previously inaccessible intracellular locations. He looks forward to advancing the company's clinical pipeline, which includes RNA-, antibody-, and enzyme-based therapies aimed at treating conditions like Duchenne muscular dystrophy, myotonic dystrophy, and other neuromuscular and immunological diseases.
